---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-23-000033"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:54:57.748596+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biohaven Q1 net loss $70.5M; cash $392M; pipeline progress, TYK2/JAK1 license acquired

## Summary
- Net loss of $70.5M ($1.03/share); non-GAAP adjusted net loss $66.7M ($0.98/share).
- Cash and marketable securities $392.0M at March 31, 2023, down from $467.9M at Dec 31, 2022.
- Acquired exclusive global rights (ex-China) to TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.
- Appointed Nick Kozauer (former FDA Division Director) as SVP of Clinical Development and Regulatory Strategy.
- Anticipates H2 2023: Phase 2/3 for BHV-7000 in epilepsy/bipolar; IND submissions for BHV-7010, -2100, -1300.

## SEC filing metadata
- accession: 0001935979-23-000033
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000033/0001935979-23-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000033/bhvn-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-23-000033
- JSON: https://secwatch.observer/filing/0001935979-23-000033.json
- Plain text: https://secwatch.observer/filing/0001935979-23-000033.txt

## Key facts
- Earnings Releases
  Biohaven Ltd. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 12, 2023, Biohaven Ltd. (the “ Registrant ”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000033/0001935979-23-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.